These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23105616)

  • 21. Addition of purified prostate specific antigen to serum from female subjects: studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin.
    Chen Z; Komatsu K; Prestigiacomo A; Stamey TA
    J Urol; 1996 Oct; 156(4):1357-63. PubMed ID: 8808871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term renal function in heart transplant recipients receiving cyclosporine therapy.
    Goral S; Ynares C; Shyr Y; Yeoh TK; Johnson HK
    J Heart Lung Transplant; 1997 Nov; 16(11):1106-12. PubMed ID: 9402509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
    Keown P; Landsberg D; Halloran P; Shoker A; Rush D; Jeffery J; Russell D; Stiller C; Muirhead N; Cole E; Paul L; Zaltzman J; Loertscher R; Daloze P; Dandavino R; Boucher A; Handa P; Lawen J; Belitsky P; Parfrey P
    Transplantation; 1996 Dec; 62(12):1744-52. PubMed ID: 8990355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma proteinase inhibitors.
    Bodmer JL; Schnebli HP
    Schweiz Med Wochenschr; 1984 Oct; 114(40):1359-63. PubMed ID: 6208604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. alpha 1-Proteinase inhibitor, alpha 1-antichymotrypsin, and alpha 2-macroglobulin are the antiapoptotic factors of vascular smooth muscle cells.
    Ikari Y; Mulvihill E; Schwartz SM
    J Biol Chem; 2001 Apr; 276(15):11798-803. PubMed ID: 11096092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum levels of alpha1-antitrypsin and alpha2-macroglobulin in lung cancer.
    Micksche M; Kokron O
    Osterr Z Onkol; 1977; 3(5-6):116-9. PubMed ID: 67586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentrations of protease and anti-protease in serum of patients with pancreatic cancer.
    Buamah PK; Skillen AW
    Clin Chem; 1985 Jun; 31(6):876-7. PubMed ID: 2581724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total serum bile acids in renal transplanted patients receiving cyclosporine A.
    Tripodi V; Nuñez M; Carducci C; Mamianetti A; Agost Carreño C
    Clin Nephrol; 2002 Nov; 58(5):350-5. PubMed ID: 12425485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha(1)-antitrypsin and antichymotrypsin in human milk: origin, concentrations, and stability.
    Chowanadisai W; Lönnerdal B
    Am J Clin Nutr; 2002 Oct; 76(4):828-33. PubMed ID: 12324297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term substitution in homozygous alpha 1-antitrypsin deficiency. Effect of the proteinase-antiproteinase equilibrium in plasma and sputum].
    Braun J; Welle S; van Wees J; Winterhoff R; Wood WG; Dalhoff K; Wiessmann KJ
    Dtsch Med Wochenschr; 1990 Jun; 115(23):889-94. PubMed ID: 2191843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function.
    Kalyoncu M; Topaloglu R; Bayrakci U; Bakkaloglu A; Besbas N; Ozaltin F; Bakkaloglu M
    Pediatr Transplant; 2006 Mar; 10(2):168-71. PubMed ID: 16573602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of cyclosporine C2 levels in long-term stable renal allograft recipients.
    Hu RH; Tsai MK; Lee PH
    Transplant Proc; 2004 Sep; 36(7):2105-7. PubMed ID: 15518762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
    Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA
    Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y; Zhang XD; Wang Y
    Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions of alpha-1-antichymotrypsin, alpha-1-proteinase inhibitor, and alpha-2-macroglobulin with the fungal enzyme, seaprose.
    Korzus E; Luisetti M; Travis J
    Biol Chem Hoppe Seyler; 1994 May; 375(5):335-41. PubMed ID: 7521171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
    Mueller EA; Kovarik JM; van Bree JB; Lison AE; Kutz K
    Transplantation; 1994 Apr; 57(8):1178-82. PubMed ID: 8178343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative study of proteinase inhibitors in human amniotic fluid and maternal serum.
    Bhat AR; Pattabiraman TN
    Br J Obstet Gynaecol; 1980 Dec; 87(12):1109-14. PubMed ID: 6159919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the interactions of human pancreatic elastase 2 with human alpha 1-proteinase inhibitor and alpha 1-antichymotrypsin.
    Davril M; Laine A; Hayem A
    Biochem J; 1987 Aug; 245(3):699-704. PubMed ID: 3499146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma alpha 1-antichymotrypsin in liver disease.
    Lindmark BE; Eriksson SG
    Clin Chim Acta; 1985 Nov; 152(3):261-9. PubMed ID: 3877579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors.
    Akhlaghi F; Keogh AM; McLachlan AJ; Kaan A
    J Heart Lung Transplant; 2001 Apr; 20(4):431-8. PubMed ID: 11295581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.